Evidence mapPaperPMID 38953181Full record

ArticleEndocrinology2024

Gut-specific Neprilysin Deletion Protects Against Fat-induced Insulin Secretory Dysfunction in Male Mice.

Nathalie Esser, Stephen M Mongovin, Breanne M Barrow, Sakeneh Zraika

Abstract read
In one paragraph

Article in Endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Nathalie EsserResearch Service, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.ORCID 0000-0003-1823-3817
Stephen M MongovinResearch Service, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.
Breanne M BarrowResearch Service, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.ORCID 0000-0002-5496-7474
Sakeneh ZraikaResearch Service, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.ORCID 0000-0003-4831-7034

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
Impact of Neprilysin on Islet FunctionR01DK098506 · NIDDK · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI ZRAIKA, SAKENEH · 2013 to 2017
$1.5M
Association Belge du DiabèteBelgian American Educational FoundationDick and Julia McAbee Endowed Postdoctoral Fellowship from the University of WashingtonFondation Horlait-DapsensFondation Léon FredericqFonds Baillet LatourNIDDK NIH HHS P30 DK017047NIDDK NIH HHS R01 DK098506NIH HHS DK-098506Société Francophone du DiabèteU.S. Department of Veterans Affairs
6 · The paper itself

Abstract

Neprilysin is a ubiquitous peptidase that can modulate glucose homeostasis by cleaving insulinotropic peptides. While global deletion of neprilysin protects mice against high-fat diet (HFD)-induced insulin secretory dysfunction, strategies to ablate neprilysin in a tissue-specific manner are favored to limit off-target effects. Since insulinotropic peptides are produced in the gut, we sought to determine whether gut-specific neprilysin deletion confers beneficial effects on insulin secretion similar to that of global neprilysin deletion in mice fed a HFD. Mice with conditional deletion of neprilysin in enterocytes (NEPGut-/-) were generated by crossing Vil-Cre and floxed neprilysin mice. Neprilysin activity was almost abolished throughout the gut in NEPGut-/- mice, and was similar in plasma, pancreas, and kidney in NEPGut-/- vs control mice. An oral glucose tolerance test was performed at baseline and following 14 weeks of HFD feeding, during which glucose tolerance and glucose-stimulated insulin secretion (GSIS) were assessed. Despite similar body weight gain at 14 weeks, NEPGut-/- displayed lower fasting plasma glucose levels, improved glucose tolerance, and increased GSIS compared to control mice. In conclusion, gut-specific neprilysin deletion recapitulates the enhanced GSIS seen with global neprilysin deletion in HFD-fed mice. Thus, strategies to inhibit neprilysin specifically in the gut may protect against fat-induced glucose intolerance and beta-cell dysfunction.

Indexed as

Diet, High-FatInsulinInsulin SecretionNeprilysinAnimalsEnterocytesGene DeletionGlucose Tolerance TestMaleMiceMice, Inbred C57BLMice, KnockoutInsulinNeprilysingutinsulin secretionmouseneprilysinoral glucose tolerance test

Identifiers

PMID38953181
PMCPMC11242446

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.